Literature DB >> 19326565

Effects of naringin on the proliferation and osteogenic differentiation of human bone mesenchymal stem cell.

Peng Zhang1, Ke-rong Dai, Shi-gui Yan, Wei-qi Yan, Chao Zhang, De-qiang Chen, Bo Xu, Zhan-wang Xu.   

Abstract

Rhizoma drynariae is used commonly in the treatment of osteoporosis and bone nonunion in traditional Chinese medicine. Modern pharmacological research indicates that naringin is the main effective component of rhizoma drynariae, which can induce the expression of the osteogenic marker in the osteoblast cell line. However, no former study has described its effect on bone mesenchymal stem cells (BMSCs). In our experiment, we co-cultured human BMSCs with different concentrations of naringin solution, then the osteogenic differentiation markers and proliferation ability were analyzed. The results indicated that a certain concentration (1-100 microg/ml) of the naringin solution may enhance the proliferation and osteogenic differentiation of human BMSCs. Also, our research explains excellently the anti-osteoporotic and bone nonunion treatment mechanism of rhizoma drynariae, thus contributing to the exploration of osteogenic differentiation agents from Chinese herbs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19326565     DOI: 10.1016/j.ejphar.2009.01.035

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  43 in total

Review 1.  Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton.

Authors:  Diptiman Chanda; Sanjay Kumar; Selvarangan Ponnazhagan
Journal:  J Cell Biochem       Date:  2010-10-01       Impact factor: 4.429

2.  Naringin rescued the TNF-α-induced inhibition of osteogenesis of bone marrow-derived mesenchymal stem cells by depressing the activation of NF-кB signaling pathway.

Authors:  Xvhai Cao; Weilong Lin; Chengwei Liang; Dong Zhang; Fengjian Yang; Yan Zhang; Xuelin Zhang; Jianyong Feng; Cong Chen
Journal:  Immunol Res       Date:  2015-07       Impact factor: 2.829

3.  Application of Chinese herbal medicines to revitalize adult stem cells for tissue regeneration.

Authors:  Hing-Lok Wong; Wing-sum Siu; Wai-ting Shum; Si Gao; Ping-Chung Leung; Chun-Hay Ko
Journal:  Chin J Integr Med       Date:  2012-12-13       Impact factor: 1.978

4.  Naringin promotes osteogenic differentiation of bone marrow stromal cells by up-regulating Foxc2 expression via the IHH signaling pathway.

Authors:  Fei-Xiang Lin; Shi-Xin Du; De-Zhong Liu; Qin-Xiao Hu; Guo-Yong Yu; Chu-Cheng Wu; Gui-Zhou Zheng; Da Xie; Xue-Dong Li; Bo Chang
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

5.  A synthetic formulation, Dhanwantharam kashaya, delays senescence in stem cells.

Authors:  S R Warrier; N Haridas; S Balasubramanian; A Jalisatgi; R Bhonde; A Dharmarajan
Journal:  Cell Prolif       Date:  2013-06       Impact factor: 6.831

6.  Inhibiting wear particles-induced osteolysis with naringin.

Authors:  Xiaowei Yu; Xingwei Zhao; Tianyi Wu; Zubin Zhou; Youshui Gao; Xinfu Wang; Chang-Qing Zhang
Journal:  Int Orthop       Date:  2012-10-31       Impact factor: 3.075

7.  Role of flavonoids on oxidative stress and mineral contents in the retinoic acid-induced bone loss model of rat.

Authors:  Nada Oršolić; Eleonora Goluža; Domagoj Dikić; Duje Lisičić; Kristijan Sašilo; Edi Rođak; Zelko Jeleč; Maja Vihnanek Lazarus; Tatjana Orct
Journal:  Eur J Nutr       Date:  2013-11-23       Impact factor: 5.614

8.  A novel porous gelatin composite containing naringin for bone repair.

Authors:  Kuo-Yu Chen; Kuen-Cherng Lin; Yueh-Sheng Chen; Chun-Hsu Yao
Journal:  Evid Based Complement Alternat Med       Date:  2013-02-04       Impact factor: 2.629

9.  Nanoparticle-labeled stem cells: a novel therapeutic vehicle.

Authors:  Abir O El-Sadik; Afaf El-Ansary; Sherif M Sabry
Journal:  Clin Pharmacol       Date:  2010-03-16

10.  Potential antiosteoporotic agents from plants: a comprehensive review.

Authors:  Min Jia; Yan Nie; Da-Peng Cao; Yun-Yun Xue; Jie-Si Wang; Lu Zhao; Khalid Rahman; Qiao-Yan Zhang; Lu-Ping Qin
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-31       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.